Business Model Breakdown
How WAVE Life Sciences Ltd Makes Money
WVE
Market Cap
$1.4B
Annual Revenue
$43M
Profit Margin
-478.3%
Employees
287
The Short Version
WAVE Life Sciences is a clinical-stage biotechnology company that designs and develops precision genetic medicines to treat rare diseases. Their core approach involves using a proprietary oligonucleotide platform, called PRISM, to create drugs that can selectively modulate RNA to address the root causes of genetic disorders. The company's current revenue primarily stems from collaborative agreements, research grants, and milestone payments from partnerships, with the long-term goal of generating substantial revenue from direct sales of its own approved therapeutic products to patients and healthcare systems.
Where the Revenue Comes From
Collaboration and license revenue (currently primary source, e.g., GSK milestones)
Future product sales from approved therapies
Who buys: Pharmaceutical partners (for collaboration revenue), ultimately patients and healthcare providers (for product sales).
Why It Works (Competitive Advantages)
- ✔Proprietary PRISM platform for oligonucleotide drug discovery and design.
- ✔Focus on precision genetic medicines targeting underlying disease causes.
- ✔Established clinical programs in high-unmet-need rare diseases (Huntington's, AATD).
Economic Moat: Narrow (Intangible Assets/IP (Proprietary PRISM platform and specific oligonucleotide chemistries))
What Our Analysis Says
DVR Score as of April 26, 2026
WAVE Life Sciences remains a high-risk, high-reward proposition with a path to 10x growth now concentrated on its rare disease pipeline (WVE-003 for Huntington's, WVE-006 for AATD) following the WVE-007 obesity data disappointment. While the company faces significant cash burn and deep unprofitability, its strong cash runway extending into 2028 provides crucial operational flexibility. Analyst sentiment remains moderately positive with an average price target significantly above the current price, indicating belief in the core assets. The upcoming U.S. redomiciliation is a positive for corporate governance, and prior insider conviction by RA Capital signals strong belief in the underlying PRISM platform. The 10x potential hinges entirely on flawless clinical execution and positive data from its lead rare disease programs.